New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 19, 2014
10:13 EDTCEO, GES, IR, LGP, LXRX, MNST, NBHGY, JOE, SCTYOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: CNOOC (CEO) downgraded to Hold from Buy at Jefferies... Guess (GES) downgraded to Neutral from Overweight at Piper Jaffray... Ingersoll-Rand (IR) downgraded at RW Baird... Lehigh Gas (LGP) downgraded to Neutral from Buy at Ladenburg... Lexicon (LXRX) downgraded to Hold from Buy at Gabelli... Monster Beverage (MNST) downgraded to Neutral from Buy at SunTrust... Nobel Biocare (NBHGY) downgraded to Hold from Buy at Berenberg... Saint Joe Co. (JOE) downgraded to Market Perform from Outperform at Raymond James... SolarCity (SCTY) downgraded at RW Baird.
News For CEO;GES;IR;LGP;LXRX;MNST;NBHGY;JOE;SCTY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 23, 2014
09:30 EDTIRIngersoll-Rand files automatic mixed securities shelf
Subscribe for More Information
06:44 EDTCEOChina to raise energy resource tax, Xinhua reports
Subscribe for More Information
October 22, 2014
09:53 EDTSCTYCredit Suisse Events at Solar Power International
Credit Suisse holds meetings in Las Vegas in conjunction with the Solar Power International Conference include ENPH, TSL, CSIQ, SCTY, JASO, HSOL and STRI on October 22.
07:09 EDTIRIngersoll-Rand sees Q4 continuing ops EPS 68c-72c, consensus 79c
Subscribe for More Information
07:08 EDTIRIngersoll-Rand sees FY14 adjusted EPS $3.20-$3.24, consensus $3.24
Sees FY14 revenue up approx. 4%, consensus $12.84B. Restructuring expenses are expected to approximate (3c) per share. Free cash flow for full-year 2014 is expected to be in the range of $800M-$850M.
07:07 EDTIRIngersoll-Rand sees acquisition of Cameron assets closing before end of year
In August, the company (IR) announced that it entered into an agreement to acquire the assets of Cameron International Corporationís (CAM) Centrifugal Compression division for $850M. The acquisition is expected to close before the end of the year, subject to regulatory approval.
07:06 EDTIRIngersoll-Rand reports Q3 continuing ops EPS $1.10, consensus $1.04
Subscribe for More Information
05:42 EDTCEOShell announces Gabon deep-water gas discovery
Shell (RDS.A, RDS.B)announced a frontier exploration discovery offshore Gabon, West Africa. The well Leopard-1 encountered a substantial gas column with around 200 metres net gas pay in a pre-salt reservoir. Leopard-1 is located around 145 kilometres off the Gabonese coast, west of Gamba. It was drilled in water 2,110 metres deep to a total vertical depth of 5,063 metres. Shell and partners are planning to undertake an appraisal programme to further determine the resource volumes. Leopard-1 was drilled in license BCD10, operated by Shell. Second partner in the venture is CNOOC (CEO). This frontier discovery follows recent deep water exploration successes in the heartlands for Shell Exploration in the Gulf of Mexico and Malaysia.
05:17 EDTLXRXIpsen, Lexicon enter into ex-North America/Japan licensing agreement
Ipsen (IPSEY) and Lexicon Pharmaceuticals (LXRX) announced that they have entered into an exclusive licensing agreement for Ipsen to commercialize telotristat etiprate outside of North America and Japan, with a focus on the treatment of carcinoid syndrome. Lexicon retains sole rights to commercialize telotristat etiprate in the United States, Canada and Japan. Lexicon is conducting Phase 3 clinical trials of telotristat etiprate for carcinoid syndrome, a serious condition caused by symptomatic neuroendocrine tumors, which produce large amounts of serotonin. Carcinoid syndrome is characterized by severe diarrhea, flushing and, in some cases, heart valve damage. Telotristat etiprate is an oral, small-molecule inhibitor of tryptophan hydroxylase, or TPH, that reduces peripheral serotonin production without affecting brain serotonin levels. Telotristat etiprate has received fast track status and orphan drug designation from the FDA, and has received orphan drug designation from the European Medicines Agency. Under the financial terms of the agreement, Lexicon is eligible to receive up to $145M, comprising $23M upfront payment and additional payments contingent upon achievement of clinical, regulatory and commercial milestones. In addition, Lexicon is also eligible to receive royalties on net sales of telotristat etiprate in the licensed territory.
October 21, 2014
15:35 EDTIRNotable companies reporting before tomorrow's open
Subscribe for More Information
October 20, 2014
11:05 EDTSCTYSolarCity appoints Jonathan Beamer as Chief Marketing Officer
Subscribe for More Information
07:19 EDTSCTYJPMorgan says recent sell-off in solar space unjustified
Subscribe for More Information
October 15, 2014
10:02 EDTMNSTOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:28 EDTMNSTMonster Beverage upgraded to Conviction Buy from Buy at Goldman
Subscribe for More Information
08:23 EDTSCTYSolarCity offers Solar Bonds to investors
Subscribe for More Information
08:07 EDTSCTYSolarCity files automatic mixed securities shelf
Subscribe for More Information
October 13, 2014
10:58 EDTSCTYSolarCity volatility elevated on wide price movement
Subscribe for More Information
08:03 EDTSCTYSolarCity lowered pricing in California, says JPMorgan
JPMorgan says SolarCity lowered its pricing in California, implementing a fixed price of 15c per watt, down from a prior average of 17c. To reflect the change, SolarCity dropped the NPV of its average new residential deployment to $1.75 per watt from $2.19 historically, the firm notes. JPMorgan cut its Retained Value estimates and dropped its price target for SolarCity shares to $74 from $83. The firm believes the price change could be tied to the proposed compression of rate tiers in 2015, allowing the company to address a larger market. It keeps an Overweight rating on SolarCity.
07:26 EDTMNSTAB InBev has studied potential deal to acquire PepsiCo, Bloomberg says
Anheuser-Busch InBev (BUD), which has a history of growth via acquisition and has been speculated to be targeting peer SABMiller (SBMRY), has also studied whether a merger with PepsiCo (PEP) makes sense, according to Bloomberg, citing people familiar with the matter. The report added that one source said no talks between Anheuser-Busch and Pepsi are ongoing, no deal is imminent, and the scenario is among many that has been examined. The report also noted that Albert Fried views Monster Beverage (MNST) and Keurig Green Mountain (GMCR) as other suitable targets for AB InBev. Reference Link
05:35 EDTCEOCNOOC reports Enping 24-2 oilfield commences production
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use